Number 846 • March 2020

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Lenoltec No. 4 Tablet (DIN 00621463) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 2, 2020**.

CODEINE PHOSPHATE/ ACETAMINOPHEN

60 MG * 300 MG TABLET

00000621463	TEVA-LENOLTEC NO. 4	TEV	\$ 0.1605
00002163918	TYLENOL NO. 4	JAI	\$ 0.2444

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Sandoz Tolterodine LA 4 mg Extended-Release Capsule (DIN 02413159) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 6, 2020**.

TOLTERODINE L-TARTRATE

4 MG EXTENDED-RELEASE CAPSULE

00002404192	MYLAN-TOLTERODINE ER	MYP	\$ 0.4911
00002413159	SANDOZ TOLTERODINE LA	SDZ	\$ 0.4911
00002412209	TEVA-TOLTERODINE LA	TEV	\$ 0.4911
00002244613	DETROL LA	PFI	\$ 2.0433

Temporary benefits added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of the following products, GLN-Olmesartan 20 mg Tablet (DIN 02469812) manufactured by Glenmark Pharmaceuticals Canada Inc., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

DIN	Product Description	Manufacturer
02442191	Act Olmesartan 20 mg Tablet	Actavis Pharma Company
02453452	Apo-Olmesartan 20 mg Tablet	Apotex Inc.
02443864	Auro-Olmesartan 20 mg Tablet	Auro Pharma Inc.
02461641	Jamp-Olmesartan 20 mg Tablet	Jamp Pharma Corporation
02461307	pms-Olmesartan 20 mg Tablet	Pharmascience Inc.
02443414	Sandoz Olmesartan 20 mg Tablet	Sandoz Canada Inc.
02318660	Olmetec 20 mg Tablet	Merck Canada Inc.

As of **February 28, 2020**, all claims for GLN-Olmesartan 20 mg Tablet (DIN 02469812) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at https://www.ab.bluecross.ca/providers/pharmacy-home.php.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Due to the unavailability of Cyclogyl 1% Ophthalmic Solution (DIN 00252506) manufactured by Alcon Canada Inc., Cyclopentolate HCl 1% Ophthalmic Solution (Minims) (DIN 02148382) manufactured by Bausch and Lomb Canada Inc., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **March 2, 2020**, all claims for Cyclopentolate HCl 1% Ophthalmic Solution (Minims) (DIN 02148382) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at https://www.ab.bluecross.ca/providers/pharmacy-home.php.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** ab.bluecross.ca/providers/pharmacy-home.php



